Search results
Results From The WOW.Com Content Network
In September 2019, Adverum announced six-month data from the first cohort of its phase I trial. [12] The stock price dropped 50% due to investor concerns over deterioration of vision that these trial subjects suffered, as well as several reports of occular inflammation. [12] In June 2020, Laurent Fischer replaced Patterson as CEO of Adverum. [13]
Investors who take an interest in Adverum Biotechnologies, Inc. (NASDAQ: ... Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Mail. Sign in. Subscriptions;
You can find instant answers on our AOL Mail help page. Should you need additional assistance we have experts available around the clock at 800-730-2563. Should you need additional assistance we have experts available around the clock at 800-730-2563.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Yahoo Finance is a media property that is part of the Yahoo network. It provides financial news, data and commentary including stock quotes , press releases , financial reports , and original content.
Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD).[3] and diabetic macular edema (DME) .
AOL latest headlines, news articles on business, entertainment, health and world events.